Moderna Completes Submission of Biologics License Application to the U.S. Food and Drug Administration for its COVID-19 Vaccine
Final blinded analysis of Phase 3 COVE study of the Moderna COVID-19 vaccine shows 93% efficacy; efficacy remains durable through six months after second dose
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 25, 2021-- Moderna, Inc. (Nasdaq:...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news
More News: COVID-19 | Drugs & Pharmacology | Food and Drug Administration (FDA) | New Drug Applications | Study | Vaccines